- Report
- June 2025
- 476 Pages
Global
From €5240EUR$5,850USD£4,467GBP
- Report
- January 2025
- 17 Pages
Global
From €13431EUR$14,995USD£11,449GBP
- Report
- November 2024
- 328 Pages
Global
From €4298EUR$4,799USD£3,664GBP
- Report
- June 2025
- 151 Pages
Global
From €3135EUR$3,500USD£2,672GBP
- Report
- September 2024
- 110 Pages
Global
From €5329EUR$5,950USD£4,543GBP
- Report
- May 2025
- 196 Pages
Global
From €3175EUR$3,545USD£2,707GBP
€3528EUR$3,939USD£3,008GBP
- Report
- May 2025
- 182 Pages
Global
From €3175EUR$3,545USD£2,707GBP
€3528EUR$3,939USD£3,008GBP
- Report
- May 2025
- 188 Pages
Global
From €3175EUR$3,545USD£2,707GBP
€3528EUR$3,939USD£3,008GBP
- Report
- May 2025
- 184 Pages
Global
From €3175EUR$3,545USD£2,707GBP
€3528EUR$3,939USD£3,008GBP
- Report
- May 2025
- 181 Pages
Global
From €3175EUR$3,545USD£2,707GBP
€3528EUR$3,939USD£3,008GBP
- Report
- May 2025
- 193 Pages
Global
From €3175EUR$3,545USD£2,707GBP
€3528EUR$3,939USD£3,008GBP
- Report
- May 2025
- 185 Pages
Global
From €3175EUR$3,545USD£2,707GBP
€3528EUR$3,939USD£3,008GBP
- Report
- May 2025
- 196 Pages
Global
From €3175EUR$3,545USD£2,707GBP
€3528EUR$3,939USD£3,008GBP
- Report
- May 2025
- 187 Pages
Global
From €3175EUR$3,545USD£2,707GBP
€3528EUR$3,939USD£3,008GBP
- Report
- May 2025
- 192 Pages
Global
From €3175EUR$3,545USD£2,707GBP
€3528EUR$3,939USD£3,008GBP
- Report
- May 2025
- 180 Pages
Global
From €3175EUR$3,545USD£2,707GBP
€3528EUR$3,939USD£3,008GBP
- Report
- May 2025
- 187 Pages
Global
From €3175EUR$3,545USD£2,707GBP
€3528EUR$3,939USD£3,008GBP
- Report
- December 2024
- 100 Pages
Global
From €3538EUR$3,950USD£3,016GBP
- Report
- August 2024
- 146 Pages
Global
From €2686EUR$2,999USD£2,290GBP
- Report
- April 2025
- 147 Pages
Global
From €2686EUR$2,999USD£2,290GBP

Type 1 diabetes is a chronic condition in which the pancreas produces little or no insulin. The market for diabetes devices specifically catered to Type 1 diabetes includes a variety of products that assist patients in monitoring and managing their blood glucose levels. Key devices within this market are blood glucose meters, continuous glucose monitoring (CGM) systems, and insulin pumps. Blood glucose meters provide immediate readings of blood glucose levels, while CGM systems offer the advantage of real-time, dynamic glucose information, revealing trends and providing alerts for rapid changes. Insulin pumps are used for the continuous subcutaneous injection of insulin, and they can often be integrated with CGM systems to create a closed-loop system, sometimes referred to as an artificial pancreas, which adjusts insulin delivery based on CGM readings.
The Type 1 diabetes devices market is marked by technological advancements that focus on improving the quality of life for patients by making devices more user-friendly, accurate, and capable of data integration for better diabetes management. Research and development in this sector are vigorous, with an emphasis on creating devices that are less invasive, more connected (leveraging smartphone technology), and capable of providing more detailed data analytics for personalized treatment plans.
Several key players in the Type 1 diabetes devices market include Medtronic, Dexcom, Abbott Laboratories, Insulet Corporation, and Tandem Diabetes Care. These companies are at the forefront of developing and providing advanced diabetes care technologies to patients, clinicians, and healthcare providers. Show Less Read more